Biofrontera AG: Biofrontera Appoints Randall Wilhoite as Chief Operating Officer of U.S. Subsidiary

Leverkusen (pta029/01.03.2017/13:45 UTC+1) Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that Randall Wilhoite has joined the Company as Chief Operating Officer of its U.S. subsidiary, effective today.

"As we continue to ramp up our sales and production of Ameluz and overall presence in the U.S., it is critical that we continue to build and maintain an efficient infrastructure that will set the stage for long-term growth," commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "Randy brings unparalleled operational experience to the team, highlighted by his successful tenure at both Siemens and Abbott, where he developed comprehensive and effective strategies in operations."

Randy brings nearly 30 years of operational experience in the pharmaceutical and medical device industries, and he has a proven track record of effectively managing and contributing to the success of multi-million dollar operations. He was most recently the Chief Operating Officer of Xagenic, where he successfully built a high performing operations infrastructure to support the company's product development and clinical evaluation of its molecular diagnostic product. He has also held senior operations positions at Siemens Healthcare Diagnostics, Anika Therapeutics and Oscient Pharmaceuticals. Randy began his career at Abbott Laboratories, where he spent more than 15 years in management positions in the company's diagnostic and medical device operations. He holds a B.A. in Chemistry from Indiana University.

Randy Wilhoite added, "Biofrontera has made great strides in laying the foundation for growth in the U.S. for its highly effective PDT drug Ameluz. With the recent U.S. commercialization of Ameluz®, I look forward to leveraging my deep operational and strategic experience to further develop the company's US operations."

Enquiries, please contact: Biofrontera AG
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
press@biofrontera.com

IR Germany: Brainwell Asset Solutions
Jürgen Benker
+49 (0) 152 08931514

IR UK: Seton Services
Toni Vallen
+44 (0) 20 7729 0805

IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui
+1 646-536-7012 / 7035
PR: Kirsten Thomas
+1 508-280-6592

About Biofrontera
Biofrontera AG (FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's lead product is Ameluz®, a prescription drug which was initially approved and marketed in Europe and is now also approved in the U.S. in combination with its medical lamp BF-RhodoLED® for photodynamic therapy (PDT) treatment (light therapy) of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma. Since January 2017 Ameluz® is also approved in the EU for the treatment of superficial and nodular basal cell carcinomas. Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now U.S. approval for a medical device/drug it has developed itself.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All Belixos® products are available in Europe through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor & public relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	press@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE0006046113 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate